合成大麻素中毒与合法大麻市场准入:2016-2019年美国国家毒物中心数据
该回顾性研究利用2016-2019年美国国家毒物数据系统(NPDS)数据,分析合成大麻素暴露报告趋势与州大麻合法化状态的关系。共报告7600例暴露,64.8%需要医疗关注,记录61例死亡;总体报告暴露随时间下降。州实施医用大麻法与小年度暴露数减少13%相关;采用宽松大麻政策与年度报告暴露降低37%独立相关(IRR 0.63,95%CI 0.50-0.79);在宽松政策州中,实施成人合法持有/使用与季度暴露减少22%相关,开设零售市场与暴露减少36%相关(相对于仅医用大麻州)。作者认为更宽松的大麻法律可能带来减少合成大麻使用动机和危害的非预期益处。
要点
- 2016-2019年NPDS共报告7600例合成大麻素暴露,64.8%需要医疗关注,记录61例死亡。
- 总体报告合成暴露在研究期间下降;州采用宽松大麻政策与年度报告暴露降低37%独立相关(IRR 0.63,95%CI 0.50-0.79)。
- 州实施医用大麻法与年度报告暴露减少13%相关。
- 在宽松政策州中,实施成人合法持有/使用与季度报告暴露减少22%相关;开设零售市场与暴露减少36%相关(相对于仅医用大麻州)。
- 作者认为更宽松的大麻法律可能带来减少合成大麻使用动机和危害的非预期益处,但为回顾性关联。
适用人群与场景
- 2016-2019年美国国家毒物数据系统(NPDS)中报告的合成大麻素暴露病例。
研究设计与关键结果
- 研究类型:回顾性研究,使用2016-2019年美国国家毒物数据系统(NPDS)数据,将合成大麻素中毒报告与州大麻法律及市场状态关联。
- 州状态分类:限制性(大麻非法或有限医用合法化)、医用(允许含THC医用大麻使用)、宽松(允许成人非医用使用含THC大麻);宽松政策州按季度细分实施成人合法持有/使用和开设零售市场。
- 统计方法:混合效应泊松回归模型,先使用年度计数在所有州中评估暴露与法律状态的关系,再在实施宽松法律的州中使用季度计数评估。
- 共报告7600例暴露;总体报告合成暴露随时间下降;64.8%需要医疗关注,记录61例死亡。
- 州实施医用大麻法与年度报告暴露减少13%相关。
- 采用宽松州大麻政策与年度报告合成暴露降低37%独立且显著相关,相对于限制性政策(IRR 0.63,95%CI 0.50-0.79)。
- 在期间实施宽松法律的州中,实施成人合法持有/使用与季度报告暴露减少22%相关。
- 开设零售市场与报告暴露减少36%相关,相对于仅医用大麻州。
证据类型、等级与局限
- 证据类型:基于美国国家毒物数据系统(NPDS)的回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐;作者认为更宽松的大麻法律可能带来减少合成大麻使用动机和危害的非预期益处(原文为回顾性关联)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To investigate trends in synthetic cannabinoid exposures reported to United States (US) poison control centres, and their association with status of state cannabis legalisation.
METHODS: A retrospective study of National Poison Data System (NPDS) data from 2016 to 2019 identified and associated synthetic poisoning reports with annual state cannabis law and market status. State status was categorised as restrictive (cannabis illegal or limited medical legalisation), medical (allowing THC-containing medical cannabis use) and permissive (allowing non-medical use of THC-containing cannabis by adults). We categorised a subset of states with permissive policies by their implementation of legal adult possession/use and opening retail markets, on a quarterly basis. Mixed-effects Poisson regression models assessed synthetic exposures associated with legal status, first among all states using annual counts, and then among states that implemented permissive law alone using quarterly counts.
RESULTS: A total of 7600 exposures were reported during the study period. Overall, reported synthetic exposures declined over time. Most reported exposures (64.8%) required medical attention, and 61 deaths were documented. State implementation of medical cannabis law was associated with 13% fewer reported annual exposures. Adoption of permissive state cannabis policy was independently and significantly associated with 37% lower reported annual synthetic exposures, relative to restrictive policies (IRR: 0.63, 95% CI: 0.50-0.79). Among states with permissive law during the period, implementation of legal adult possession/use was associated with 22% fewer reported quarterly exposures. Opening of retail markets was associated with 36% fewer reported exposures, relative to states with medical cannabis only.
CONCLUSIONS: Adoption of permissive cannabis law was associated with significant reductions in reported synthetic cannabinoid exposures. More permissive cannabis law may have the unintended benefit of reducing both motivation and harms associated with use of synthetic cannabis products.
参考来源
- Klein TA, Dilley JA, Graves JM, et al. Synthetic cannabinoid poisonings and access to the legal cannabis market: findings from US national poison centre data 2016-2019. Clin Toxicol (Phila). 2022. PMID: 35942512. doi:10.1080/15563650.2022.2099887
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。